Crinetics Pharmaceuticals, Inc. (CRNX) Stock Overview
Explore Crinetics Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Crinetics Pharmaceuticals, Inc. (CRNX)
Key Financials
Key Financials
Market Cap
8.9B
P/E Ratio
-16.62
EPS (TTM)
$-5.13
ROE
-0.44%
CRNX Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Crinetics Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of CRNX on the NASDAQ shows an RSI of 90.58, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $55.61 for the NASDAQ listing.
Key metrics behind Crinetics Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of -16.62 and a market capitalization of 8.9B. Combined with our AI analysis, these give both institutional and retail investors a clear view of CRNX on the NASDAQ.